TABLE 3.
Comparison of sarcopenic and non-sarcopenic patients (n = 52)
| Variable | Sarcopenic, n = 25 | Non-sarcopenic, n = 27 | P value |
|---|---|---|---|
| Sex, n (%) female | 13 (52.0%) | 8 (29.6%) | .157 |
|
| |||
| Age at MRI | 16.0 (15.0, 17.0) | 14.0 (9.0, 18.0) | .242 |
|
| |||
| Duration of disease from diagnosis to MRI, months | 32.0 (2.0, 52.0) | 14.0 (2.0, 33.0) | .205 |
|
| |||
| Diagnosis, n (%) | |||
| AIH | 11 (44%) | 17 (63%) | .266 |
| ASC/PSC | 14 (56%) | 10 (37%) | |
| IBD present, n (%) | 10 (40%) | 9 (33%) | .774 |
| BUN (mg/dL) | 9.5 (8.0, 12.0) | 11.0 (10.0, 14.0) | .023 |
| Creatinine (mg/dL) | 0.7 (0.5, 0.8) | 0.6 (0.5, 0.8) | .467 |
| AST (U/L) | 34.0 (23.0, 69.0) | 37.0 (28.0, 83.0) | .458 |
| ALT (U/L) | 40.0 (26.0, 82.0) | 65.0 (43.0, 89.0) | .394 |
| Direct bilirubin (mg/dL) | 0.1 (0.1, 0.3) | 0.1 (0.1, 0.3) | .798 |
| GGT (U/L) | 54.0 (15.0, 141.0) | 40.0 (19.0, 174.0) | .956 |
| Albumin (g/dL) | 3.7 (3.5, 4.1) | 3.8 (3.6, 4.1) | .673 |
| INR (s) | 1.1 (1.0, 1.2) | 1.1 (1.1, 1.2) | .559 |
| L3/4 subcutaneous fat area (mm2) | 10 332 (5536, 18 992) | 8916 (4864, 13 880) | .360 |
| L3/4 subcutaneous fat thickness (mm) | 16 (11, 30) | 13 (10, 19) | .085 |
| L3/4 visceral fat area (mm2) | 3156 (2064, 7492) | 2084 (688, 3092) | .005 |
| L3/4 visceral fat thickness (mm) | 70 (55, 84) | 56 (49, 74) | .099 |
Note: N (%) for categorical variable; medians (IQRs) for numeric variables.
Abbreviations: AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ASC, autoimmune sclerosing cholangitis; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; GGT, gamma glutamyl transferase; IBD, inflammatory bowel disease; INR, international normalized ratio; IQR, interquartile range; MRI, magnetic resonance imaging; PSC, primary sclerosing cholangitis.